Page URL:

Clarification: Gene test aims to predict reproductive lifespan

15 November 2009
By BioNews
Appeared in BioNews 534

In BioNews 533, we reported on a new study suggesting an association between early ovarian decline and variations in the number of DNA sequence 'CGG' repeats present in a gene called FMR1. Whilst this finding is novel, we would like to clarify that the FMR1 gene has been known for many years, since the presence of excess CGG repeats causes the common genetic condition Fragile X syndrome in boys who inherit the mutation.

The usual number of CGG repeats present in the FMR1 gene is between 10-40, while a repeat number of 55-200 is described as a 'premutation'. This number of repeats causes genetic instability, so a woman carrying a premutation may pass on a 'full mutation' of between 200-1000 repeats, which causes Fragile X syndrome in boys who inherit it. In the latest study, the researchers found that women with fewer or greater than 28-33 repeats had lower levels of anti-Mullerian hormone (AMH), which suggests they have fewer eggs in their ovaries.

It has also been pointed out to us that any future test of ovary function based on this information would also reveal whether a woman is carrying a Fragile X premutation. Since this could give rise to new reproductive implications, the decision to take such a test should therefore not be taken lightly or without full explanation. A corrected version of this story is available online at the link below.

9 November 2009 - by Rosie Beauchamp 
The discovery that variations in a gene called FMR1 could indicate the length of a woman's fertility by indicating the rate at which her egg supply will diminish may enable some women to find out how long they are likely to remain fertile. It is currently difficult to predict which women will experience premature ageing of their ovaries, but Norbert Gleicher at the Center of Human Reproduction in New York believes he will be able to study variations in a gene known as FMR1 - mutations in whic...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.